Interesting info from todays presentation. SGI-1776 will have data at this conference, in combination with chemo. Stated that ETK target is called the hallmark of cancer target. Looks like s-110 will also be used as a combination drug with cisplatan. Mentioned that our latest drugs are creating academic excitement, this helps get the word our for recruiting for trials.